Tag: Obstructive Sleep Apnea (OSA)
UPDATED: Apnimed files for IPO, FDA accepts application
July 14, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC). The company has also announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application filing for Oxnimbi, an oral treatment for obstructive sleep apnea (OSA).
In its Form S-1, the company acknowledges positive airway pressure (PAP) as the current standard of care for OSA, but notes many patients refuse or discontinue the treatment...
Apnimed files for IPO
July 10, 2026HME News Staff
CAMBRIDGE, Mass. – Apnimed has filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) as it awaits approval from the U.S. Food & Drug Administration for Oxnimbi, an oral treatment for obstructive sleep apnea (OSA).
In its Form S-1, the company acknowledges positive airway pressure (PAP) as the current standard of care for OSA, but notes many patients refuse or discontinue the treatment due to issues such as discomfort, pressure intolerance and lifestyle...
New therapies challenge CPAP, but providers aren’t shifting yet
June 19, 2026Liz Beaulieu, Editor
YARMOUTH, Maine – There may be an increasing number of options to treat obstructive sleep apnea (OSA), but CPAP remains the top choice, say 68% of respondents to a recent HME Newspoll.
“The sleep apnea treatment landscape is becoming increasingly diverse, which is good news for patients,” wrote one respondent. “New options, such as oral appliances, implantable devices and emerging medications may help people who struggle with CPAP therapy. That said, CPAP remains the gold...
Health Canada approves Zepbound for OSA
June 17, 2026HME News Staff
TORONTO – Health Canada has approved Eli Lilly Canada’s Zepbound for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity in combination with a reduced-calorie diet and increased physical activity. Lilly says Zepbound is the first medication approved in Canada for this indication, offering a new option for people living with a sleep-related breathing disorder closely linked with obesity. “Zepbound's approval for the treatment of obstructive...
ProSomnus, MonitAir collaborate to facilitate clinical visibility into OSA
June 16, 2026HME News Staff
SAN FRANCISCO – ProSomnus Sleep Technologies and MonitAir, a digital health and telemonitoring platform for sleep medicine, have collaborated to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ OSA Device will be able to view, organize and remotely monitor patient data within the MonitAir platform. The companies say the integration is intended to facilitate...
Sleep therapy growth at inflection point
June 10, 2026HME News Staff
Sleep therapy is expanding across new channels, technologies and care settings, creating more ways than ever to diagnose and treat obstructive sleep apnea – and giving providers new opportunities to shape the patient journey, despite its growing complexity, industry experts say.
“Demand remains strong because obstructive sleep apnea continues to be significantly underdiagnosed, but the pathway into therapy is changing rapidly,” said Robin Randolph, senior vice president of sales...
Daybreak to make OAT available to veterans nationwide
June 10, 2026HME News Staff
LOS ANGELES – Daybreak has entered into a distribution partnership with Veterans Healthcare Supply Solutions (VHSS), a Service-Disabled Veteran Owned Small Business (SDVOSB), to make oral appliance therapy (OAT) for obstructive sleep apnea (OSA) available to veterans through VA Healthcare facilities nationwide. Obstructive sleep apnea disproportionately affects the veteran population, with studies estimating that OSA is among the most prevalent service-connected conditions in the United States....
Zepbound, Shaq launch national OSA awareness campaign
June 10, 2026HME News Staff
INDIANAPOLIS – Eli Lilly and Company has announced that basketball legend and cultural icon Shaquille O'Neal is sharing his personal experience with moderate obstructive sleep apnea (OSA), including candid insight into his diagnosis and treatment journey with Zepbound (tirzepatide). After years of dismissing fatigue, loud snoring and difficulty focusing as normal parts of his life, O'Neal learned they were actually symptoms of moderate-to-severe OSA. Moderate-to-severe OSA is a serious...
Lilly’s investigational GLP-1 reduces AHI by up to 36 events per hour in OSA patients
June 8, 2026HME News Staff
INDIANAPOLIS – Eli Lilly, the maker of Zepbound and Foundayo, has announced positive results from Phase 3 trials of retatrutide, an investigational GLP-1, showing substantial weight loss along with meaningful improvements across knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and Type 2 diabetes – common obesity-related conditions.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos,"...
F&P fields questions on mask pipeline, tariff impact
May 27, 2026Liz Beaulieu, Editor
AUCKLAND, New Zealand – Analysts pressed Fisher & Paykel Healthcare executives during a recent earnings call on the company’s lack of new full-face mask launches for obstructive sleep apnea (OSA), even as other product categories continue to gain traction.
Analyst Ben Crozier described the full-face mask category as “a bit of a headwind” for F&P, noting it has been offset by more recent and frequent launches in other categories, including the F&P Solo (nasal), F&P Nova...